Enisoprost
Grundinformationen
- CAS
81026-63-3- Standard-SMILES
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CC/C=C\CCC(=O)OC- InChIKey
CIBHDGPIOICRGX-ZQCHCGQNSA-N- Summenformel
- C22H36O5
- Durchschnittliche Molmasse
- 380,5 g/mol
- Monoisotopische Masse
- 380,25627424
Namen und Bezeichner
- Bevorzugter Name
- Enisoprost
- IUPAC
- methyl (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-4-enoate
- Englischer Name
- ENISOPROST
- Summenformel
- C22H36O5
- Molmasse
- 380.52
Namen und Synonyme
ENISOPROST81026-63-3EnisoprostumSC-34301J85F4K48Q1DTXSID20102162711,16-dihydroxy-16-methyl-9-oxoprost-4,13-dien-1-oic acidRefChem:920955DTXCID201506637SC 34301Enisoprostum [Latin]Enisoprost [USAN:INN]
Weitere Namen anzeigen
Prosta-4,13-dien-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (4Z,11α,13E)-(±)-
UNII-J85F4K48Q1methyl (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-4-enoate(+-)-Methyl (Z)-7-((1R,2R,3R)-3-hydroxy-2-((E)-(4RS)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentyl)-4-heptenoateProsta-4,13-dien-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (4Z,11alpha,13E)-(+-)-ENISOPROST [INN]Enisoprost (USAN/INN)ENISOPROST [USAN]ENISOPROST [MART.]
Datenbank-Bezeichner
- CAS
81026-63-3- PubChem CID
- 5311219
- DTXSID
DTXSID201021627- ChEMBL
CHEMBL266979- UNII
- J85F4K48Q1
- Nikkaji
- J355.405H
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 2,9
- Polarare Oberfläche (TPSA)
- 83,8 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 13
- Schwere Atome
- 27
- Formalladung
- 0
- Komplexität
- 525
Physikochemische Eigenschaften
- Siedepunkt
- 490.2 · 490.2±45.0 °C(Predicted)
- Dichte
- 1.092 · 1.092±0.06 g/cm3(Predicted)
- pka
- 13.9 · 13.90±0.60(Predicted)
Chemie und Industrie
Pharmakologische Informationen
MeSH Pharmacological Classification
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Anwendungen
VerwendenEnisoprost is the antisecretory prostaglandin derivative. Analogue of Prostaglandin E1 (P838600), which is the primary prostaglandin that is easily crystallized from purified biological extracts.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter
Wird geladen…
Öffentliche Anfragen
Wird geladen…
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…